Compare GSK plc (GSK) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JetBlue Airways Corporation — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while JetBlue Airways Corporation trades at $3.85 (market cap $1.48B). The key difference: GSK plc is far larger — about 62.1× JetBlue Airways Corporation's market cap, and GSK plc pays a 3.9% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and JetBlue Airways Corporation for 44 Days on average.
| GSK | JBLU | |
|---|---|---|
Market Cap | $91.88B | $1.48B |
Volume | 7,730,529 | 30,275,693 |
Sector | Health | Industrials |
52-Week High | $61.18 | $6.46 |
52-Week Low | $43.24 | $3.92 |
Typical Hold Time | 93 Days | 44 Days |
Enterprise Value | $111.88B | $8.84B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
JetBlue (JBLU) trades at $3.86, down 2.77% today, reflecting persistent bearish technical signals and weak earnings. The company reported a net loss of $602 million in 2025, with negative profit margins and declining revenue. Recent news includes route expansion to Colombia but also reduced capacity guidance due to weather and fuel costs. Technical indicators are bearish, with the stock trading near support levels.
The outlook remains challenging with high debt levels and consistent losses. Analyst consensus is mixed but leans hold, with a $5.89 price target suggesting potential upside if operational improvements materialize. Key risks include elevated fuel prices, competitive pressure, and macroeconomic sensitivity. Investment appeal is limited to speculative recovery bets amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
